Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May-Jun;22(3):175-8.
doi: 10.1097/PPO.0000000000000189.

BRAF-Directed Therapy in Metastatic Colorectal Cancer

Krittiya Korphaisarn  1 , Scott Kopetz
Affiliations
Review

BRAF-Directed Therapy in Metastatic Colorectal Cancer

Krittiya Korphaisarn et al. Cancer J. 2016 May-Jun.

Abstract

Activating BRAF (V-raf murine sarcoma viral oncogene homolog B) mutations occur in approximately 5% to 10% of patients with metastatic colorectal cancer, mostly V600E mutation, and it is associated with distinct clinical and pathological features. To date, there are no approved treatments to target this mutation. BRAF inhibitor monotherapy has limited efficacy, in contrast to metastatic melanoma. Combination strategies that block not only BRAF mutated kinase but other alternative pathways are ongoing and have demonstrated improved activity. This review aims to provide data about new strategies to target to BRAF gene mutation in metastatic colorectal cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have declared that no conflict of interest exists

Figures

Figure 1
Figure 1
The combination treatment strategies in BRAF mutant CRC CRC=colorectal cancer; EGFR=epidermal growth factor receptor; BRAF= V-raf murine sarcoma viral oncogene homolog B; MEK=mitogen-activated extracellular signaling kinase; PIK3CA= phosphatidylinositol 3-kinase, catalytic subunit alpha; Bcl-2= B-cell lymphoma 2; i, inh.= inhibitor
Figure 2
Figure 2
Actionable drugs in proliferation pathway that have been evaluated in BRAFmut CRC
See this image and copyright information in PMC

References

    1. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934. - PubMed
    1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. - PubMed
    1. Ikenoue T, Hikiba Y, Kanai F, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 2003;63:8132–8137. - PubMed
    1. MA BB, MO F, Tong JH, et al. Elucidating the prognostic significance of KRAS, NRAS,BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer. Asia Pac J Clin. 2015;11:160–169. - PubMed
    1. Kawazoe A, Shitara K, Fukuoka S, et al. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer. 2015;15:258. - PMC - PubMed

MeSH terms

Substances